https://finance.nine.com.au/business-news/stocks-to-watch/ffb2390d-d07b-4d78-b881-3e8e26cc02da
From Channel 9 finance...
ANP - ANTISENSE THERAPEUTICS - up three cents, or 63.8 per cent, to 7.7 cents
Early results from a small phase II clinical trial of the Melbourne biopharmaceutical company's muscular dystrophy therapy has found no issues with safety, with the drug appearing to slow progression of the disease.
The trial involved nine non-ambulatory boys with duchenne muscular dystrophy being treated at Royal Children's Hospital.
Antisense says its ATL1102 drug could help ease the inflamation related with the deadly disease and be a complimentary treatment to corticosteroids.
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-127
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $177.5K | 1.730M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 136159 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 233891 | 3 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |